In this episode of LifeSci Continuum, I’m joined by David Iannetta to explore why it’s never too early to plan for your company’s exit strategy. Many companies focus solely on getting a product to market, but the most successful ones know that preparing for an exit—whether it’s an IPO, acquisition, or becoming a standalone company—starts long before the launch. David draws on his extensive experience with IPOs and acquisitions to explain how early-stage planning builds credibility and ensures long-term success.
David shares his insights on the importance of integrating exit strategy planning into your product launch process. Whether your goal is to go public, get acquired, or remain independent, successful life sciences companies always consider their exit options from the start. This planning is essential for life sciences firms due to the high stakes of product development and the significant investments needed for commercialization.
David explains how early decisions about sales channels, partnerships, and distribution can shape a company’s trajectory, ensuring they’re positioned for long-term growth and success. For life sciences companies, where the path from R&D to market is complex and costly, having a clear exit plan ensures adaptability and strategic flexibility in the face of future challenges.
Follow Bill: / founderandcdo
Contact Bill: https://meshagency.com/lets-connect/
Video Podcast: / @billschickfcmo
Audio Podcast: https://www.buzzsprout.com/2380430
Follow Dave: / dave-iannetta
